Table 2.

Baseline characteristics of the HEMO (n=1409) and LDO (n=10,392) cohorts across binary Nadir90-defined IDH

CharacteristicHEMO CohortLDO Cohort
(+) Nadir90 (n=167)(−) Nadir90 (n=1242)(+) Nadir90 (n=1055)(−) Nadir90 (n=9337)
Age (per 10 yr)60.5±12.858.2±13.964.2±13.861.2±14.9
Women108 (64.7%)676 (54.4%)548 (51.9%)4220 (45.2%)
Black97 (58.1%)808 (65.1%)330 (31.3%)3860 (41.3%)
ICEDaaa
 ≤130 (18.0%)448 (36.1%)
 254 (32.3%)404 (32.5%)
 383 (49.7%)390 (31.4%)
Diabetes88 (52.7%)543 (43.7%)644 (61.0%)5593 (59.9%)
Heart failure71 (42.5%)505 (40.7%)479 (45.4%)4167 (44.6%)
Peripheral vascular disease62 (37.1%)313 (25.2%)424 (40.2%)4325 (46.3%)
Cerebrovascular disease36 (21.6%)248 (20.0%)40 (3.8%)283 (3.0%)
Coronary artery disease79 (47.3%)484 (39.0%)163 (15.5%)1278 (13.7%)
Vintage (yr)
 ≤1.037 (22.2%)326 (26.2%)233 (22.1%)2667 (28.6%)
 1.1–1.933 (19.8%)248 (20.0%)137 (13.0%)1467 (15.7%)
 2.0–3.930 (17.9%)291 (23.4%)243 (23.0%)2326 (24.9%)
 ≥4.067 (40.1%)377 (30.4%)440 (41.7%)2860 (30.6%)
 Missing002 (0.2%)17 (0.2%)
Access
 Graft101 (60.5%)752 (60.6%)328 (31.3%)2876 (31.0%)
 Fistula46 (27.5%)410 (33.0%)338 (32.3%3486 (37.6%)
 Catheter20 (12.0%)90 (6.4%)382 (36.4%)2909 (31.4%)
Post-HD weight (kg)b
 Quartile 140 (24.0%)313 (25.2%)292 (27.7%)2309 (24.7%)
 Quartile 239 (23.4%)313 (25.2%)267 (25.3%)2330 (25.0%)
 Quartile 336 (21.5%)316 (25.4%)248 (23.5%)2348 (15.1%)
 Quartile 452 (31.1%)300 (24.2%)248 (23.5%)2350 (25.2%)
Treatment time delivered (min)213.5±23.0211.1±23.0216.5±28.8215.0±28.5
UF volume (L)2.9±0.92.9±0.92.8±1.22.7±1.2
Pre-HD SBP (mmHg)
 ≤12967 (40.1%)114 (9.2%)488 (46.2%)911 (9.8%)
 130–15973 (43.7%)665 (53.5%)429 (40.7%)4940 (52.9%)
 ≥16027 (16.2%)463 (37.3%)138 (13.1%)3486 (37.3%)
Nonoliguric (>200 ml/d)a10 (6.0%)140 (11.3%)aa
Albumin (g/dl)
 ≤2.97 (4.2%)45 (3.6%)97 (9.2%)425 (4.6%)
 3–3.9150 (89.8%)1026 (82.6%)595 (56.4%)5048 (54.1%)
 ≥410 (6.0%)171 (13.8%)359 (34.0%)3795 (40.6%)
 Missing004 (0.4%)69 (0.7%)
Hematocrita (%)33.8±4.533.1±4.2aa
Hemoglobina (g/dl)aa12.1±1.412.2±1.4
Hospitalized during exposure periodc61 (36.5%)376 (30.3%)332 (31.5%)2811 (30.1%)
β-Blocker use30 (18.0%)362 (29.2%)89 (8.5%)839 (9.0%)
Calcium channel blocker49 (29.3%)643 (51.8%)84 (8.0%)964 (10.3%)
Renin-angiotensin system blocker use27 (16.2%)314 (25.3%)98 (9.3%)910 (9.8%)
Nitrate use33 (19.8%)221 (17.8%)33 (3.1%)275 (3.0%)
α-Blocker use3 (1.8%)76 (6.1%)1 (0.1%)120 (1.3%)
Other antihypertensive use14 (8.4%)306 (24.6%)80 (7.6%)940 (10.1%)
High Kt/V groupa86 (51.5%)623 (50.2%)aa
 equilibrated Kt/Vaaa
 <1.2209 (19.8%)2152 (23.0%)
 ≥1.2812 (77.0%)6850 (73.4%)
 Missing34 (3.2%)335 (3.6%)
High-flux groupa91 (54.5%)613 (49.4%)aa
  • Positive (+) IDH defined as meeting the Nadir90 defined IDH definition (minimum intradialytic SBP<90 mmHg) in ≥30% of exposure period dialysis sessions. Values are presented as mean (SD) or n (%).

  • a Not available in both cohorts.

  • b HEMO cohort (quantile 1: ≤62.7, quantile 2: 62.8–74.1, quantile 3: 74.2–89.1, quantile 4: ≥89.2 kg); LDO cohort (quantile 1: ≤58.7, quantile 2: 58.8–67.7, quantile 3: 67.8–78.1, quantile 4: ≥78.2).

  • c Missed HD sessions used as a surrogate for hospitalizations in LDO cohort.